|
Drug development firm Synvista Therapeutics (formerly Alteon) is working on new prescriptions for diabetes and heart disease, and may have found a little Rx of its own. The struggling biotech merged with privately held HaptoGuard in 2006, after its lead candidate for hypertension (called alagebrium) failed in a clinical trial. Through the merger, the company gained an investigational diagnostic product that tests for a certain protein variant that indicates a high risk of heart disease in diabetes patients. HaptoGuard also contributed a potential drug compound (ALT-2074) that would treat those patients. Synvista continues development on alagebrium as a treatment for diastolic heart failure and kidney disease.
|
|
Headlines
for
Synvista Therapeutics, Inc.
| | • |
SYNVISTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Notice of Delisting or Fa
EDGAR Online
-
Thu Feb 26, 2009 | | • |
SYNVISTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online
-
Wed Jan 28, 2009 | | • |
SYNVISTA THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
EDGAR Online
-
Wed Dec 24, 2008 | | • |
SYNVISTA THERAPEUTICS, INC. Financials
EDGAR Online Financials
-
Fri Dec 5, 2008 |
|
More Headlines...
|
| | | Contact Information | |
Address: |
221 W. Grand Ave.
Montvale, NJ 07645
| | Phone: | 201-934-5000 | | Fax: | 201-934-8880 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2007): | 0.10 M | | Revenue Growth (1 yr): | (-79.60%) | | Employees (2007): | 9 | | Employee Growth (1 yr): | (-30.80%) |
|
|
Key People
| | • |
President, CEO, and Director:
Noah Berkowitz
| | • |
CFO:
Wendy A. Milici
| | • |
Senior Director Marketing and Sales:
David C. Tantillo
|
|
|
